HSD17B2

Across TCGA pan-cancer cohorts, HSD17B2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HSD17B2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HSD17B2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where HSD17B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.579	1.000	<.001	51	view →
PDAC	OS	Tertile	II,III,IV	0.947	0.778	.001	46	view →
COAD	DFS	Median	III,IV	1.000	0.835	.032	36	view →
LUAD	OS	Median	All	0.918	1.000	.010	8	view →
UCEC	OS	Median	All	1.000	0.851	.006	8	view →
HNSC	DFS	Tertile	II,III,IV	0.794	1.000	.015	6	view →
LSCC	DFS	Tertile	III,IV	1.000	0.478	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HSD17B2–CCRCC (DFS)

Open the CCRCC breakdown →